Synairgen

Synairgen is a University spin-off and public limited company (plc) [2][1][3] working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The company develops drugs for respiratory diseases including COVID-19.[4][5][6][7][8]

Synairgen PLC
IndustryDrug discovery
Biotechnology
Founded2003 (2003)[1]
Founder
Headquarters,
Websitesynairgen.com

A subsidiary of the company, Synairgen Research Limited,[9] works on research and development.[10][11]

References

  1. Anon (2016). "SYNAIRGEN PLC". companieshouse.gov.uk. London: Companies House.
  2. Anon (2020). "SYNAIRGEN PLC SNG Stock". londonstockexchange.com. London Stock Exchange.
  3. Rowlatt, Justin (July 20, 2020). "Covid treatment trial described as 'breakthrough'". bbc.co.uk. BBC News.
  4. Anon (2020). "COVID-19 at Synairgen". synairgen.com. Synairgen.
  5. Neate, Rupert (July 24, 2020). "'Major' breakthrough in Covid-19 drug makes UK professors millionaires". theguardian.com. The Guardian.
  6. Anon (2020). "Expert reaction to announcement by Synairgen that their drug SNG001 has had positive results in initial trials on COVID-19 patients". Science Media Centre.
  7. Donnelly, Laura (July 20, 2020). "Coronavirus drug hailed as game-changer after trial finds it cuts chances of severe illness". telegraph.co.uk. Daily Telegraph.
  8. Holgate, Stephen; Agusti, Alvar; Strieter, Robert M.; Anderson, Gary P.; Fogel, Robert; Bel, Elisabeth; Martin, Thomas R.; Reiss, Theodore F. (2015). "Drug development for airway diseases: looking forward". Nature Reviews Drug Discovery. 14 (6): 367–368. doi:10.1038/nrd4645. ISSN 1474-1776. PMID 26000726.
  9. Anon (2020). "SYNAIRGEN RESEARCH LIMITED". companieshouse.gov.uk. Companies House.
  10. "Synairgen SNG001". research.cmft.nhs.uk. National Health Service.
  11. Graham, Flora (2020). "Daily briefing: Three vaccines show early promise for COVID-19". nature.com. Springer Nature.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.